The vocation of the CIML is to produce discoveries which advance our knowledge of the role and functioning of our immune system. Some of these discoveries open up new diagnostic or therapeutic avenues, in which case the scientist explores their clinical potential and sometimes patents them.
Today, the CIML manages patents and licences agreements. It has also spawned many spinoffs, including Immunotech, Innate Pharma and Ipsogen, and has forged partnerships with pharmaceutical companies and biotechnology firms.
These industrial agreements, articulated around converging interests, meet three complementary objectives:
- To accelerate research process by sharing complementary scientific and technological expertise
- To rapidly transform the therapeutic targets discovered by the CIML into drug candidates
- To contribute to the “immunological know-how” of the scientists of the biopharmaceutical industry.
